期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
低分子肝素钠治疗不稳定型心绞痛临床观察 被引量:3
1
作者 张林 刘亚荣 《陕西医学杂志》 CAS 2009年第8期1060-1061,共2页
目的:探讨低分子肝素钠治疗不稳定型心绞痛(UA)的临床疗效及安全性。方法:选择住院UA患者80例,随机分为治疗组40例与对照组40例,对照组常规服用阿司匹林、他汀类、硝酸盐类、β-受体阻滞剂和血管紧张素转化酶抑制剂等,治疗组在对照组常... 目的:探讨低分子肝素钠治疗不稳定型心绞痛(UA)的临床疗效及安全性。方法:选择住院UA患者80例,随机分为治疗组40例与对照组40例,对照组常规服用阿司匹林、他汀类、硝酸盐类、β-受体阻滞剂和血管紧张素转化酶抑制剂等,治疗组在对照组常规抗心绞痛治疗的基础上,加用低分子肝素钠5000IU,皮下注射,12h1次,连用7d,连续观察2周,比较两组疗效及不良反应。结果:治疗组总有效率为95.0%,对照组总有效率77.5%,两组比较有显著性意义(P<0.05),治疗组有3例出现皮下瘀斑,无需要处理出血的并发症。结论:低分子肝素钠对控制UA、预防急性心肌梗死(AMI)的发生安全可靠,且无明显毒副作用,值得推广应用。 展开更多
关键词 心绞痛 不稳定型/药物疗法 @低分子肝素钠 对比研究
下载PDF
低分子肝素钠联合棓丙酯治疗进展性脑梗死62例 被引量:3
2
作者 刘蔚玲 孟林 《陕西医学杂志》 CAS 2009年第8期1061-1063,共3页
目的:探讨棓丙酯联合低分子肝素钠治疗进展性脑梗死的临床疗效。方法:应用棓丙酯联合低分子肝素钠治疗进展性脑梗死62例,并设对照组62例进行分析。结果:治疗组神经功能缺损程度评分与对照组比较明显降低(P<0.01),总有效率与对照组均... 目的:探讨棓丙酯联合低分子肝素钠治疗进展性脑梗死的临床疗效。方法:应用棓丙酯联合低分子肝素钠治疗进展性脑梗死62例,并设对照组62例进行分析。结果:治疗组神经功能缺损程度评分与对照组比较明显降低(P<0.01),总有效率与对照组均有明显差异(P<0.01)。结论:棓丙酯联合低分子肝素钠治疗进展性脑梗死具有较好效果,值得临床推广。 展开更多
关键词 脑梗塞/药物疗法 @棓丙酯 @低分子肝素钠 对比研究
下载PDF
Comparison of fondaparinux sodium and low molecular weight heparin in the treatment of hypercoagulability secondary to traumatic infection 被引量:3
3
作者 Baiqiang Li Kang Wang +2 位作者 Xin Zhao Chao Lin Haichen Sun 《Chinese Journal of Traumatology》 CAS CSCD 2015年第3期147-149,共3页
Purpose: To compare the effects and side-effects of fondaparinux sodium and low molecular weight heparin in patients with hypercoagulability accompanied with traumatic infection. Methods: Thirty-six patients with po... Purpose: To compare the effects and side-effects of fondaparinux sodium and low molecular weight heparin in patients with hypercoagulability accompanied with traumatic infection. Methods: Thirty-six patients with post-traumatic infections in our hospital intensive care center were diagnosed with hypercoagulability from February 2012 to February 2013. These patients were randomly divided into 2 groups. In group F (18 patients), the patients were treated with fondaparinux sodium, 2.5 rag, 1/d for 11 d. In group L (18 patients), the patients were treated with low molecular weight heparin, 4100 U, 1/12 h for 11 d. The incidence of deep vein thrombosis, bleeding events and multiple organ dysfunction syndrome (MODS) and mortality of two groups after anticoagulation therapy were analyzed. Fibrinogen, D-dimer level and activity of antithrombin Ⅲ were measured by the coagulation analyzer. Results: The incidence of deep vein thrombosis, MODS incidence and mortality were not significantly different between the two groups. The rate of bleeding evens in group F was lower than group L (p 〈 0.05). Antithrombin Ⅲ got an upward trend after anticoagulant therapy, in which it was higher in group F than in group L on the 5th d and llth d (p 〈 0.05). Fibrinogen levels were gradually increased, and there was no significant difference between two groups (p 〉 0.05). D-dimer was significantly decreased after anticoagulant therapy for 5 d (p 〈 0.01 ), and there were significant differences between two groups on the 5th d and 7th d (p 〈 0.05). It showed no significant difference on the llth d (p 〉 0.05). Conclusion: Fondaparinux sodium and low molecular weight heparin can effectively improve coagulopathy in patients with traumatic infection. Compared with low molecular weight heparin, fondaparinux sodium may reduce the risk of bleeding events in patients with hypercoagulability accompanied by traumatic infection. 展开更多
关键词 Traumatic infection Blood coagulation disorder Fondaparinux Heparin LOW-MOLECULAR-WEIGHT
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部